Navigation Links
Language centers revealed, brain surgery refined with new mapping
Date:1/2/2008

lso allows for smaller craniotomies that expose only the tumor and a small margin of surrounding brain tissue, rather than several centimeters or more of the patients brain. After the craniotomy, the neurosurgeon maps the brain by stimulating a section (1 cm by 1 cm) at a time with a bipolar electrode. The strategy does not require positive identification of language sites (defined as an arrest in speech, inability to name objects or read, or difficulty in articulating words), as in traditional brain mapping, but rather is driven by localization of negative sites -- areas that contain no language function.

Nearly half our patients had no positive language sites in the area exposed, yet their functional outcomes remained nearly identical or better than patients who underwent extensive positive language mapping, said Sanai. In addition, our results show that negative language mapping can be relied upon even when language function is already affected by tumor growth.

Language mapping, originally created to help guide epilepsy surgery, has proved to be an essential tool in helping neurosurgeons identify which parts of the tumor can be safely removed and in protecting patients from damage to speech and language centers, according to Berger. This is the largest study of its kind to show that this technique can be further refined for brain tumor resection without harming the patient.

The language map generated during the study shows that areas processing language function in the brain are widely distributed, sometimes varying in location by as much as several centimeters from patient to patient. This has implications for language organization models, which are currently based on the assumption that specific language functions have fixed anatomical locations.

Over eight years, Berger and his team tested negative language mapping on a total of 250 consecutive patients (146 men and 104 women), all of whom had gliomas -- a common a
'/>"/>

Contact: Vanessa deGier
vdegier@pubaff.ucsf.edu
415-476-2557
University of California - San Francisco
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Insight into the struggles of children with language impairments
2. Babies raised in bilingual homes learn new words differently than infants learning one language
3. Toy Blocks Might Boost Toddlers Language Skills
4. GetWellNetwork Expands Foreign Language Support for the PatientLife System
5. Hospitals Say New Cordless Phone Helps Communication With Patients Who Speak Diverse Languages
6. JGIM: studies show importance of language services on disparities, quality of care
7. Studies Show Importance of Language Services on Reducing Disparities, Increasing Quality of Patient Care
8. Language Assistance Lacking at Resurrection Hospitals
9. Medtronic Mediterranean Launches Worlds First Arabic-Language Integrated Insulin Therapy for Improved Diabetes Management
10. Language barriers adversely impact health-care quality
11. NINDS Announces New Spanish-Language Website
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2008)...und by purchasing the Green Bracelet at www.simmon...wire/ -- The Diamond Empowerment Fund (D.E.F.), He...together to host the exclusive "Empowerment for Af...day evening in recognition of World AIDS Day. D.E.... including Tamsin Smith , President of the (RED) ...
(Date:12/4/2008)...anuary issue of European Urology , the official j...ished by Elsevier, will feature new recommendation...lated by major scientific organizations. LOH is a ...advancing age and characterized by typical symptom..., Late-onset hypogonadism (LOH) is caused by a d...
(Date:12/4/2008)...o are exposed to environmental tobacco smoke have ...ssion and other behavioral problems, according to ...cal Center. , In a study posted online ahead of ...ral Pediatrics , the researchers said behavioral p..., but they added even low levels of tobacco smoke ...
(Date:12/4/2008)...irstCall/ -- Transgenomic,(OTC Bulletin Board: TB...r,Research of Houston, Texas through its technolo...dation, has granted the Company an exclusive licen... DNA (mtDNA) damage detection.,The patents form t...n,cardiovascular disease, diabetes, degenerative ...
Breaking Medicine News(10 mins):Health News:On World AIDS Day, Russell Simmons and Special Guests Attended 'Empowerment for Africa' Dinner 2Health News:New recommendations by scientific societies about late-onset hypogonadism 2Health News:Study strengthens link between tobacco smoke and behavioral problems in boys with asthma 2Health News:Study strengthens link between tobacco smoke and behavioral problems in boys with asthma 3Health News:Transgenomic Obtains Exclusive License to Mitochondrial DNA Damage Detection Technology 2Health News:Transgenomic Obtains Exclusive License to Mitochondrial DNA Damage Detection Technology 3Health News:Transgenomic Obtains Exclusive License to Mitochondrial DNA Damage Detection Technology 4Health News:Transgenomic Obtains Exclusive License to Mitochondrial DNA Damage Detection Technology 5Health News:Transgenomic Obtains Exclusive License to Mitochondrial DNA Damage Detection Technology 6
...eorgia have found that, although a vacuum device p...'s cup size, few women may have the time and commi... BRAVA system, requires women to wear two plastic ...0 weeks straight.// The domes are connected to a b...
...e likely for Cesarean delivery, says Dr.Bell from ... one of the major causes of maternal mortality. //...eathe under general anesthesia, so a woman's risk ...ombined. Bell and colleagues studied more than 300...
...mounts of water is very essential for an individua...es of water a day, says a leading physiologist. We... two litres of water a day that's eight glasses//...ater balance expert Dr Heinz Valtin of Dartmouth M...
...researchers of University of Houston, a new study ... patients is associated with manageable side effec...to neuropathy.They examined the effects of escalat...Patients received oral thalidomide starting at 200...
Other Medicine News:Health News:Vacuum device increase breasts 2
(Date:12/3/2008)...E PLAINS, N.Y., Dec. 3 The Leukemi...ntly announce the beginning of a new clinical tria...f California, San Diego (UCSD). , , LLS ...t will speed the development and approval of a nov...abine refractory and/or 17p deleted chronic lympho...
(Date:12/3/2008)...DIEGO, Dec. 3 Vical Inco...lusive, binding letter of intent with EIP,Eczacib...ing of the company,s,Allovectin-7(R) immunotherap...,Republic of Northern Cyprus. EIP has agreed to ob...erritory and to pay Vical upfront and milestone pa...
(Date:12/2/2008)...OLLA, Calif., Dec. 2 TorreyPines T...d positive results from a 26 patient Phase II tria...for xerostomia, or dry mouth, in patients with Sjo...of a statistically significant increase in salivar... doses: 10 mg, 15 mg, and 20 mg. These doses were ...
(Date:12/1/2008)...VILLE, Md., Dec. 1 Vanda...blication in The Lancet , one of the world,s lead...f its novel circadian regulator, experimental comp...jaratnam et al(1) is entitled "Melatonin agonist t...sleep-time shift: two randomised controlled multic...
Breaking Medicine Technology:The Leukemia & Lymphoma Society and Memgen Announce New Chronic Lymphocytic Leukemia Clinical Trial 2The Leukemia & Lymphoma Society and Memgen Announce New Chronic Lymphocytic Leukemia Clinical Trial 3Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 2Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 3Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 4Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 5TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 2TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 3TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 4TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 5Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 2Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 3Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 4Thermo Fisher Scientific Expands Clinical Trial Services Capabilities with New Facility in India 4416 1Thermo Fisher Scientific Expands Clinical Trial Services Capabilities with New Facility in India 4416 2Thermo Fisher Scientific Expands Clinical Trial Services Capabilities with New Facility in India 4416 3Thermo Fisher Scientific Expands Clinical Trial Services Capabilities with New Facility in India 4416 4Cardiac Science Corporation Schedules Third Quarter Earnings Release and Announces Conference Call 4412 1Cardiac Science Corporation Schedules Third Quarter Earnings Release and Announces Conference Call 4412 2CV Therapeutics Announces Presentations at American Heart Association Scientific Sessions 2007 1448 1CV Therapeutics Announces Presentations at American Heart Association Scientific Sessions 2007 1448 2CV Therapeutics Announces Presentations at American Heart Association Scientific Sessions 2007 1448 3PPD Reports Third Quarter 2007 Financial Results 3B Announces Increase in Annual Cash Dividend From 240 12 to 240 40 Per Year 1444 1PPD Reports Third Quarter 2007 Financial Results 3B Announces Increase in Annual Cash Dividend From 240 12 to 240 40 Per Year 1444 2PPD Reports Third Quarter 2007 Financial Results 3B Announces Increase in Annual Cash Dividend From 240 12 to 240 40 Per Year 1444 3PPD Reports Third Quarter 2007 Financial Results 3B Announces Increase in Annual Cash Dividend From 240 12 to 240 40 Per Year 1444 4PPD Reports Third Quarter 2007 Financial Results 3B Announces Increase in Annual Cash Dividend From 240 12 to 240 40 Per Year 1444 5PPD Reports Third Quarter 2007 Financial Results 3B Announces Increase in Annual Cash Dividend From 240 12 to 240 40 Per Year 1444 6
...Pluristem Life Systems,Inc. (OTCBB:PLRS), a cell ... of products for a variety of indications,announc...rs at the,13th Annual Meeting of the International...2007 in Sydney Australia., Pluristem CEO and Chair... more attention from the scientific community as o...
...ogen Idec (NASDAQ: BIIB),and Elan Corporation, plc...e TOUCH Prescribing Program(TM) and TYGRIS safety ...nical studies of,TYSABRI(R) (natalizumab). Also pr... Academy of Neurology in Boston, MA were extension...ed treatment,effect on clinical relapses and the r...
Other Medicine Technology:Pluristem to Present Two Scientific Posters at the International,Society for Cellular Therapy 2Pluristem to Present Two Scientific Posters at the International,Society for Cellular Therapy 3Data Presented at the American Academy of Neurology's Annual,Meeting Provide Update on Utilization and Safety of Tysabri in,Patients with Multiple Sclerosis 2Data Presented at the American Academy of Neurology's Annual,Meeting Provide Update on Utilization and Safety of Tysabri in,Patients with Multiple Sclerosis 3Data Presented at the American Academy of Neurology's Annual,Meeting Provide Update on Utilization and Safety of Tysabri in,Patients with Multiple Sclerosis 4Data Presented at the American Academy of Neurology's Annual,Meeting Provide Update on Utilization and Safety of Tysabri in,Patients with Multiple Sclerosis 5Data Presented at the American Academy of Neurology's Annual,Meeting Provide Update on Utilization and Safety of Tysabri in,Patients with Multiple Sclerosis 6
Basic ergonomic chairs with concave seats and standard-sized backrests with lumbar support • Select options like seats, backrests, armrests, and casters and glides. • BTP/1Q-PAL chairs are
Basic ergonomic chairs with concave seats and standard-sized backrests with lumbar support • Select options like seats, backrests, armrests, and casters and glides. • BTP/1Q-PAL chairs are
Basic ergonomic chairs with concave seats and standard-sized backrests with lumbar support • Select options like seats, backrests, armrests, and casters and glides. • BTN/1Q-CAB chairs are
Basic ergonomic chairs with concave seats and standard-sized backrests with lumbar support • Select options like seats, backrests, armrests, and casters and glides. • BTN/1Q-CAB chairs are
Medicine Products: